"Durability of Uncertainty Endures"
The chemical and pharmaceutical industries are grappling with the challenges posed by constantly changing tariff announcements, as they adapt to the evolving trade landscape between the EU and the USA.
A joint statement has been issued by the EU and the USA, but some points still require clarification. The average tariffs for chemical or pharmaceutical products, when averaged, are below 15%, yet significantly higher than before Trump's second presidency. The cap at 15% for European exports remains a hope, but concerns exist about the USA developing new tariffs exceeding the base rate.
Chemical companies, being suppliers to other sectors like automotive and electronics, also face indirect impacts from tariffs. The pharmaceutical industry, in particular, is affected by direct tariffs due to its large exports to the USA.
The weakening of the dollar under Trump's administration makes it harder for European exporters to remain competitive. In response, the EU has established a monitoring instrument to react immediately if China or another economy floods the European market with its own products.
The ongoing geopolitical tensions and increased pressure on exports due to tariffs make navigation more difficult for VCI member companies. Matthias Blum, a trade expert at the Chemical Association (VCI), states that erratic trade and economic policies have led to a high degree of uncertainty for European chemical and pharmaceutical companies exporting to the USA.
The VCI expects significant turbulence in global trade flows and some companies are carefully observing certain developments. The adaptation effort for chemical companies includes strategic questions about the use of Mexican plants for duty-free exports to the USA. Financing the transformation will be more difficult due to funding cuts in the USA and high energy costs and regulatory burdens in Europe.
Investment in the USA is expensive due to high costs for skilled labor and plant construction, and investment costs are currently difficult to predict. A westward trek of companies investing and producing in the USA is not expected due to high costs, complex approval procedures, and regulatory burdens in Europe.
The uncertainty created by the USA's trade and economic policies is causing many companies to adopt a wait-and-see approach. Higher tariffs may be imposed on pharmaceutical products following the USA's Section 232 national security investigations. The belief that the uncertainty will decrease is waning, with many expecting it to persist long-term.
Despite the lack of a named source in the provided search results, a representative from the Association of the Chemical Industry in Germany discussed the impact of trade agreements with the USA on companies in an interview with the Financial Times. The agreement has prevented a mutual escalation of tariffs and counter-tariffs.
The VCI also anticipates that some companies may be closely watching certain developments, with the potential for significant changes in global trade flows. The EU's efforts to maintain a level playing field and protect its industries from unfair competition will continue to be a key focus in the coming months and years.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Trump's Policies: Tariffs, AI, Surveillance, and Possible Martial Law
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
- Abdominal Fat Accumulation: Causes and Strategies for Reduction
